[go: up one dir, main page]

IS8026A - Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun - Google Patents

Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun

Info

Publication number
IS8026A
IS8026A IS8026A IS8026A IS8026A IS 8026 A IS8026 A IS 8026A IS 8026 A IS8026 A IS 8026A IS 8026 A IS8026 A IS 8026A IS 8026 A IS8026 A IS 8026A
Authority
IS
Iceland
Prior art keywords
amyloids
combinations
methods
antibodies against
antibodies
Prior art date
Application number
IS8026A
Other languages
English (en)
Inventor
Mercken Mark
M. Benson Jacqueline
Original Assignee
Centocor, Inc.
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc., Janssen Pharmaceutica N.V. filed Critical Centocor, Inc.
Publication of IS8026A publication Critical patent/IS8026A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS8026A 2003-03-28 2005-09-14 Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun IS8026A (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45846903P 2003-03-28 2003-03-28
US45847403P 2003-03-28 2003-03-28
US45851003P 2003-03-28 2003-03-28
US45850903P 2003-03-28 2003-03-28
PCT/US2004/009522 WO2005028511A2 (en) 2003-03-28 2004-03-26 Anti-amyloid antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
IS8026A true IS8026A (is) 2005-09-14

Family

ID=34382160

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8026A IS8026A (is) 2003-03-28 2005-09-14 Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun

Country Status (9)

Country Link
US (1) US20050129695A1 (is)
EP (1) EP1613657A2 (is)
KR (1) KR20060054174A (is)
AU (1) AU2004274390A1 (is)
CA (1) CA2520853A1 (is)
EA (1) EA200501524A1 (is)
IS (1) IS8026A (is)
NO (1) NO20055018L (is)
WO (1) WO2005028511A2 (is)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20060024667A1 (en) * 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
KR20070040824A (ko) 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
ES2318918B1 (es) * 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1951892A4 (en) * 2005-11-22 2009-01-14 Univ Pennsylvania ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES
EP1963363A2 (en) * 2005-11-30 2008-09-03 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ１〜４２特異的モノクローナル抗体
ES2422556T3 (es) 2006-01-09 2013-09-12 Romark Lab Lc Tratamiento de hepatitis vírica
AU2007218318A1 (en) * 2006-02-24 2007-08-30 Chiesi Farmaceutici S.P.A. Anti-amyloid immunogenic compositions, methods and uses
WO2007145589A1 (en) * 2006-06-15 2007-12-21 Per Arvidsson Peptides that are capable of binding to amyloid-beta peptide.
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2008156622A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
US20100172919A1 (en) * 2007-06-15 2010-07-08 Jan Grimm Noveltreatment for neurological disorders
WO2009048538A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
PL2238166T3 (pl) * 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
CN102762220A (zh) * 2007-10-15 2012-10-31 森托科尔奥索生物科技公司 人抗淀粉样蛋白抗体、组合物、方法和用途发明背景
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2009222199A1 (en) * 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid beta activity of intravenous immunoglobulin (IVIG) in vitro
US8501178B2 (en) 2008-11-25 2013-08-06 Biogen Idec Ma Inc. Use of DR6 and p75 antagonists to promote survival of cells of the nervous system
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CA2780319A1 (en) 2009-11-12 2011-05-19 Genentech, Inc. A method of promoting dendritic spine density
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
SG188285A1 (en) 2010-09-02 2013-04-30 Vaccinex Inc Anti-cxcl13 antibodies and methods of using the same
US20120121574A1 (en) * 2010-11-15 2012-05-17 Luciano Polonelli Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
AU2013225812B2 (en) 2012-03-02 2017-11-30 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
NZ710744A (en) 2013-01-31 2020-07-31 Vaccinex Inc Methods for increasing immunoglobulin a levels
IL242088B2 (en) 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
CN106535889A (zh) 2014-02-10 2017-03-22 帕塔拉制药有限责任公司 用于治疗肺疾病的肥大细胞稳定剂
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
AU2015360579A1 (en) 2014-12-10 2017-05-18 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CA3037746A1 (en) 2016-10-07 2018-04-12 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11242398B2 (en) 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
JP2023506450A (ja) * 2019-12-11 2023-02-16 アンベテックス ピーティーワイ エルティーディー 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物
TW202216760A (zh) 2020-07-23 2022-05-01 愛爾蘭商歐薩爾普羅席納有限公司 抗類澱粉β (ABETA)抗體
WO2025250457A1 (en) 2024-05-28 2025-12-04 University Of Rochester Enhanced brain transduction by gene therapeutics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1172378A1 (en) * 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2002088307A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
AU2002258808A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
JP2005500389A (ja) * 2001-08-17 2005-01-06 イーライ・リリー・アンド・カンパニー Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
CA2520853A1 (en) 2005-03-31
WO2005028511A2 (en) 2005-03-31
US20050129695A1 (en) 2005-06-16
EP1613657A2 (en) 2006-01-11
KR20060054174A (ko) 2006-05-22
AU2004274390A1 (en) 2005-03-31
NO20055018L (no) 2005-12-05
WO2005028511A3 (en) 2005-09-09
NO20055018D0 (no) 2005-10-27
EA200501524A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
IS8026A (is) Mótefni gegn amýlóíðum, samsetningar, aðferðir ognotkun
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
NL1026829A1 (nl) Gemodificeerde humane IGF-1R-antilichamen.
DK1599504T3 (da) Modificeret antistof
ATE412220T1 (de) Fft-architektur und -verfahren
FI20041529L (fi) Sormiliimaliitos, -ristikko ja -menetelmä
FI20030261A0 (fi) Iskulaite
DE502005005268D1 (de) Spalierobst-, insbesondere beeren- oder traubenerntefahrzeug und -verfahren
ATA13202003A (de) Sitzmöbel
NO20053189D0 (no) HVC-kombinasjonsterapi.
FR2856713B1 (fr) Perfectionnements au hourdis composite
DE502004011994D1 (de) Verbund
SE0303065D0 (sv) New composition, methods and uses thereof
ES1054082Y (es) Servilletero perfeccionado.
ES1054922Y (es) Trituradora-cosechadora de maleza y similares.
DE602004015963D1 (de) Rke
ITVI20030127A1 (it) Solaio in latero - cemento.
ITPI20030083A1 (it) Bottale con perfezionamenti costruttivi adatti, in
ES1056707Y (es) Llavero clasificador perfeccionado.
NL1029156A1 (nl) Apparaat en werkwijze.
ITMO20030025A1 (it) Imballaggio e metodo.
ES1057334Y (es) Edredon y colcha edredon.
ES1056476Y (es) Columpio.
ITPG20040024A1 (it) Tinti e maltinti di bacco